Our results further strengthen the findings of a recent meta-analysis including 25 independent studies, showing that APOE ε4-carriers who were also KL-VSHET+, were at a reduced risk for the combined outcome of conversion to mild cognitive impairment (MCI) or AD [6]. This evidence concerns the gene APOE and Alzheimer disease.